Lupus drug anifrolumab under pregnancy safety spotlight
NCT ID NCT07049653
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This study is tracking 500 pregnant women with lupus to see if the drug anifrolumab is linked to birth defects or pregnancy loss. Researchers will compare women who took anifrolumab during early pregnancy to those who did not. The goal is to gather real-world safety data, not to test the drug's effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- anifrolumab
- What this could lead to
- If successful, this study could provide important safety information about using anifrolumab during pregnancy for women with lupus.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't test if anifrolumab works. Results may be limited by the data available and cannot prove cause and effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
RECRUITINGCary, North Carolina, 27513, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new biologic tame lupus flares?
- Could a single injection tame lupus and Sjögren's?
- Can a single infusion tame tough lupus?
- Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.
- Can genetics and environment explain lupus in the gullah population?
- Can a smartphone app bridge the lupus care gap for women of color?